Skip to Content

Lorazepam injectable presentations

Last Updated: April 4, 2017
Status: Current

Lorazepam injectable presentations

Products Affected - Description
  • Ativan injection, West-Ward
    2 mg/mL, 1 mL vial, 25 count (NDC 00641-6001-25)

4 mg/mL, 10 mL vial, 10 count (NDC 00641-6002-10)
 
Lorazepam injection, Akorn
2 mg/mL, 1 mL vial, 10 count (NDC 17478-0040-01)
 
Lorazepam injection, Pfizer
2 mg/mL, 1 mL Carpuject syringe, 10 count (NDC 00409-1985-30)
2 mg/mL, 1 mL vial, 10 count (NDC 00409-6778-02)
 
Lorazepam injection, West-Ward
2 mg/mL, 1 mL vial, 25 count (NDC 00641-6044-25)
4 mg/mL, 10 mL vial, 10 count (NDC 00641-6047-10)
Reason for the Shortage
    • Bedford discontinued lorazepam injection in May, 2011.1
    • West-Ward has product on shortage due to manufacturing delays.2
    • Pfizer has product on shortage due to increased demand and manufacturing delays.3
    • Akorn has not provided a reason for the shortage.4
    • Amphastar has product available.5
Available Products
  • Ativan, West-Ward

2 mg/mL, 10 mL vial, 10 count (NDC 00641-6000-10)
4 mg/mL, 1 mL vial, 25 count (NDC 00641-6003-25)
 
Lorazepam, Amphastar
2 mg/mL, 10 mL vial, 10 count (NDC 76329-8261-01)
 
Lorazepam injection, Pfizer
2 mg/mL, 10 mL vial, 10 count (NDC 00409-6780-02)
4 mg/mL, 1 mL Carpuject syringe, 10 count (NDC 00409-1539-31)
4 mg/mL, 1 mL vial, 10 count (NDC 00409-6779-02)
4 mg/mL, 10 mL vial, 10 count (NDC 00409-6781-02)
 
Lorazepam injection, West-Ward
2 mg/mL, 10 mL vial, 10 count (NDC 00641-6046-10)
4 mg/mL, 1 mL vial, 25 count (NDC 00641-6045-25)

Estimated Resupply Dates

    • Akorn has lorazepam 2 mg/mL 1 mL vials on intermittent back order and is releasing product as it becomes available.4
    • Pfizer has lorazepam 2 mg/mL 1 mL vials and 1 mL Carpuject syringes available in limited supply.3
    • West-Ward has lorazepam 2 mg/mL 1 mL vials and 4 mg/mL 10 mL vials on a weekly allocation.2
    • West-Ward has Ativan 2 mg/mL 1 mL vials on back order and the company estimates a release date of mid-April to mid-May 2017. The 4 mg/mL 10 mL vials are on a weekly allocation.2

Implications for Patient Care

  • Lorazepam injection is labeled for treatment of status epilepticus and as premedication for the relief of anxiety and tension in patients undergoing surgical procedures. Off-label uses of lorazepam injection include sedation in the critical care setting for patients on mechanical ventilation, treatment of acute delirium, and adjunctive treatment of chemotherapy induced nausea and vomiting.6-8

Alternative Agents & Management

    • During this shortage, use alternative injectable benzodiazepines.
    • There are no direct dosage conversions between the benzodiazepines because each has a distinct pharmacokinetic profile that dictates the agent’s therapeutic use and dosing. The table below compares the pharmacokinetics of injectable benzodiazepines.
    Table. Pharmacokinetics of Injectable Benzodiazepines10-11,7-9  

    Agent

    Onset of Action
    Intravenous (min)

    Onset of Action
    Intramuscular (min)

    Duration of Action
    Intravenous (hours)

    Duration of Action
    Intramuscular (hours)

    Half-life (hours)

    Active Metabolites

    Diazepam

    1 to 5

    Intramuscular administration results
    in slow and erratic absorption

    0.3 to 0.5

    Intramuscular administration results
     in slow and erratic absorption

    20 to 120

    Yes

    Lorazepam

    5 to 20

    15 to 30

    6 to 8

    6 to 8

    8 to 15

    No

    Midazolam

    1 to 5

    5 to 15

    < 2a

    2a

    3 to 11

    Yes

     
    a The pharmacologic effect of midazolam may last up to 6 hours in some patients.

References

    1. Bedford (personal communications). April 4 and 20, May 3 and 18, and July 6, 2011.
    2. West-Ward (personal communications). April 4 and 20, May 18, June 13, July 5, August 10, September 23, October 25, November 23 and 30, December 15 and 20, 2011; and January 12 and 20, February 29, March 28, April 20, May 17, June 21, July 5, 2012, August 6 and 16, September 4 and 26, October 11, November 5, 16, and 30, December 17, 2012; January 23, March 27, April 1 and 17, May 22, June 13, July 10, August 5, September 12 and 23, October 4 and 28, November 22, 2013; January 14, 18, and 31, February 14, March 3, 7, 20, and 28, April 11 and 28, May 16 and 30, June 18, July 10, August 8, September 3 and 24, October 29, November 5, 19, and 26, 2014; January 7, February 4, March 4 and 18, April 8, May 13, June 17, July 8, August 26, September 22, 2015; February 25, March 24 and 29, May 3 and 13, July 1, August 23, September 29, November 9 and 10, December 15, 2016; January 4 and 11, March 15, and April 4, 2017.
    3. Pfizer (personal communications and website). April 4 and 22, and May 20, June 17, August 8, September 22, October 25, November 23 and 30, December 12 and 20, 2011; and January 9 and 26, February 29, March 28, April 17, May 17, June 18, July 3 and 24, August 6 and 27, September 5 and 24, October 11, November 5 and 14, December 5 and 19, 2012; January 23, March 27, April 1 and 17, May 14, June 12, July 10, August 5, September 12 and 23, October 2 and 28, December 2, 2013; January 8 and 22, February 6 and 14, March 5, 10, and 20, April 1, 14, and 29, May 19, June 2 and 26, July 11, August 8, September 11 and 26, October 29, November 5 and 19, December 1, 2014; January 7 and 26, February 4, March 9 and 31, April 13, May 15, June 18, July 16, September 10, 2015; February 25, March 24, April 8, May 3 and 17, July 1, September 7, October 26, November 9 and 21, December 19, 2016; January 5, 12, and 26, February 9, March 15, and April 4, 2017.
    4. Akorn (personal communications). December 16 and 20, 2011; January 11 and 26, March 30, April 17, May 9, June 12, July 26, August 9 and 16, September 5, October 11, 2012; May 22, June 15, September 9 and 23, December 2, 2013; January 8, March 3, April 14, May 19, June 23, August 8, September 11 and 25, November 3 and 21, 2014; January 7, March 9 and 31, April 13, May 13, September 2, 2015; February 25, March 21, April 8 and 29, July 1, August 26, October 11, 2016; and January 4 and 11, February 8, and March 14 and 24, 2017.
    5. Amphastar (personal communications). November 9, 2012; January 7, April 17, May 13, June 10 and 25, July 22, September 12 and 23, October 28, 2013; January 10 and 27, February 24, March 10 and 24, April 28, May 12, June 9, August 8, 2014, September 9 and 21, October 29, November 10, December 1 and 22, 2014; February 2, March 4 and 18, April 8, May 8, June 8, July 14, September 2, 2015; February 25, August 17, 2016; and March 20, 2017.
    6. Ativan injection product information. Deerfield, IL: Baxter Healthcare Corp., November 2006.
    7. McEvoy, G. K., E. K. Snow, et al., Eds. (2011). AHFS DI (Lexi-Comp Online). Bethesda, MD, American Society of Health-System Pharmacists.
    8. Wickersham, R. M., K. K. Novak, et al., Eds. (2010). Drug Facts and Comparisons (eFacts). St. Louis, MO, Wolters Kluwer Health, Inc.
    9. Aminoff MJ, Greenberg DA, Simon RP, eds. Clinical Neurology. 6th ed. New York, NY: Lange Medical BooksMcGraw-Hill; 2005.
    10. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. Mar 2010;17(3):348-355.
    11. Millikan D, Rice B, Silbergleit R. Emergency treatment of status epilepticus: current thinking. Emerg Med Clin North Am. Feb 2009;27(1):101-113, ix.

Updated

Updated April 4, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 23, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide